JP2023521634A - 炎症状態を処置または予防するための方法および組成物 - Google Patents

炎症状態を処置または予防するための方法および組成物 Download PDF

Info

Publication number
JP2023521634A
JP2023521634A JP2022559967A JP2022559967A JP2023521634A JP 2023521634 A JP2023521634 A JP 2023521634A JP 2022559967 A JP2022559967 A JP 2022559967A JP 2022559967 A JP2022559967 A JP 2022559967A JP 2023521634 A JP2023521634 A JP 2023521634A
Authority
JP
Japan
Prior art keywords
hydroxychloroquine
cbd
axis
oral administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022559967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521634A5 (https=
Inventor
レイサム，ジョエル・ブラッドリー
アガーワル，スダンシュ
ブリークレイ，マーク・ロバート
Original Assignee
インカネックス・ヘルスケア・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901030A external-priority patent/AU2020901030A0/en
Application filed by インカネックス・ヘルスケア・リミテッド filed Critical インカネックス・ヘルスケア・リミテッド
Publication of JP2023521634A publication Critical patent/JP2023521634A/ja
Publication of JP2023521634A5 publication Critical patent/JP2023521634A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022559967A 2020-04-02 2021-03-15 炎症状態を処置または予防するための方法および組成物 Pending JP2023521634A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
AU2020901030A AU2020901030A0 (en) 2020-04-02 A method of treatment
AU2020901030 2020-04-02
AU2020902432A AU2020902432A0 (en) 2020-07-14 A method of treatment
AU2020902432 2020-07-14
AU2020903985 2020-11-02
AU2020903985A AU2020903985A0 (en) 2020-11-02 A method of treatment
AU2020904264 2020-11-18
AU2020904264A AU2020904264A0 (en) 2020-11-18 A method of treatment
AU2021900241A AU2021900241A0 (en) 2021-02-03 A method of treatment
AU2021900241 2021-02-03
AU2021900324 2021-02-10
AU2021900324A AU2021900324A0 (en) 2021-02-10 A method of treatment
PCT/AU2021/050226 WO2021195691A1 (en) 2020-04-02 2021-03-15 Methods and compositions for treating or preventing an inflammatory condition

Publications (2)

Publication Number Publication Date
JP2023521634A true JP2023521634A (ja) 2023-05-25
JP2023521634A5 JP2023521634A5 (https=) 2024-03-18

Family

ID=77926837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559967A Pending JP2023521634A (ja) 2020-04-02 2021-03-15 炎症状態を処置または予防するための方法および組成物

Country Status (8)

Country Link
US (1) US20230128114A1 (https=)
EP (1) EP4125835A4 (https=)
JP (1) JP2023521634A (https=)
AU (1) AU2021250462A1 (https=)
CA (1) CA3169702A1 (https=)
CO (1) CO2022015048A2 (https=)
IL (1) IL296943A (https=)
WO (1) WO2021195691A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240325312A1 (en) * 2021-07-15 2024-10-03 Incannex Healthcare Limited Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule
WO2024025525A1 (en) * 2022-07-27 2024-02-01 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07196508A (ja) * 1993-10-29 1995-08-01 Univ Georgetown 移植片対宿主疾患の治療のための医薬組成物
JP2002511411A (ja) * 1998-04-14 2002-04-16 ザ マティルダ アンド テレンス ケネディ インスティチュート オブ リューマトロジー 抗炎症剤
JP2005509648A (ja) * 2001-11-09 2005-04-14 ローレン チャロウス、 炎症性腸疾患の治療方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200009077A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Compositions for treating dermatological diseases
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07196508A (ja) * 1993-10-29 1995-08-01 Univ Georgetown 移植片対宿主疾患の治療のための医薬組成物
JP2002511411A (ja) * 1998-04-14 2002-04-16 ザ マティルダ アンド テレンス ケネディ インスティチュート オブ リューマトロジー 抗炎症剤
JP2005509648A (ja) * 2001-11-09 2005-04-14 ローレン チャロウス、 炎症性腸疾患の治療方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIO & MED CHEM, vol. 23:1377-1385, JPN6025007758, 2015, ISSN: 0005537491 *
BIOSCI TRENDS, vol. 14(2):156-158, JPN6025007761, March 2020 (2020-03-01), ISSN: 0005537494 *
EUR J PHARMACOL, vol. 843:251-259, JPN6025007760, 2019, ISSN: 0005537493 *
IMMUNOPHARMA IMMUNOTOXIN, vol. 37(1):35-41, JPN6025007757, 2005, ISSN: 0005537490 *
J ALLERGY CLIN IMMUNOL, vol. 102(2):198-203, JPN6025007759, 1998, ISSN: 0005537492 *

Also Published As

Publication number Publication date
AU2021250462A1 (en) 2022-12-01
WO2021195691A1 (en) 2021-10-07
IL296943A (en) 2022-12-01
EP4125835A4 (en) 2024-05-22
EP4125835A1 (en) 2023-02-08
CO2022015048A2 (es) 2022-11-08
US20230128114A1 (en) 2023-04-27
CA3169702A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
Burnett et al. Final report of the safety assessment of kojic acid as used in cosmetics
CN117338783A (zh) 哌啶基-吲哚衍生物的用途
JP2023521634A (ja) 炎症状態を処置または予防するための方法および組成物
EP2087886B1 (en) Therapeutic agent for rheumatoid arthritis
JPH10504014A (ja) Ｓｓｉチルホスチンと薬剤組成物
US20210236580A1 (en) Methods and Compositions for Mitigating Symptoms of Acute Respiratory Distress Syndrome
KR102635831B1 (ko) Cxcl11에 의한 m2 대식세포의 재분극 유도를 통한 폐섬유화증 치료 용도
Jiang et al. Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome
CN114917209B (zh) 白皮杉醇在抗弓形虫感染的应用
US20160175310A1 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins
JP2001503067A (ja) チゾキサニドおよびニタゾキサニドの薬剤の合成物
CN1845737A (zh) 富脂质斑的稳定化方法和破裂的预防方法
JP2024524680A (ja) 固定用量配合カプセル中にカンナビジオールとヒドロキシクロロキンとを含有する組成物
TWI775408B (zh) 用以治療與嗜中性白血球激活失調及趨化相關之疾病的方法
DE10218328A1 (de) Mittel zur präventiven Therapie nach akutem Schlaganfall
DE60109286T2 (de) Mittel und verfahren zur erhöhung des chaperonin-spiegels im gehirn
JP7244121B2 (ja) 好中球の活性化及び動員の異常調節に関連する疾患の治療方法
US20220339122A1 (en) Methods for the treatment of diseases associated with dysregulated activation and recruitment of neutrophils
RU2413504C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-6-НИТРОИМИДАЗО[2,1-b]ОКСАЗОЛА
WO2004028540A1 (ja) 抗神経変性薬
KR102351311B1 (ko) 포리아 추출물 및 활성성분의 폐 손상의 변형, 예방 및/또는 치료에의 적용
US12023329B2 (en) Methods for the treatment of diseases associated with activation of inflammasomes
JP7360297B2 (ja) オートファジー活性化剤
WO2020213616A1 (en) A composition for prevention and/or treatment for alzheimer's disease and/or alzheimer dementia, and a composition for reducing amyloid-beta oligomer neurotoxicity
WO2024040119A2 (en) Compositions and methods for the treatment of cardiac arrhythmias, including atrial fibrillation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402